(22 days)
Not Found
No
The document describes a wound dressing with silver for antimicrobial properties. There is no mention of any computational or analytical capabilities that would suggest the use of AI or ML.
Yes
The device is a wound dressing that contains silver, which is released upon contact with wound exudate to manage "exuding wounds with delayed healing due to bacteria, or where there is a risk of infection." This suggests a therapeutic action to promote healing and mitigate infection.
No.
This device is a wound dressing designed for the management and healing of wounds, not for diagnosing conditions.
No
The device description clearly states it is a wound dressing made of physical materials (polyurethane foam, topfilm) and contains silver, indicating it is a physical medical device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Description: The description clearly states that Biatain Ag Foam Dressings are "wound dressings for exuding wounds." They are applied directly to the wound surface.
- Intended Use: The intended use is for the "management of moderately to highly exuding leg ulcers and pressure sores," and other types of wounds. This is a therapeutic application, not a diagnostic test performed on a sample.
- Lack of Diagnostic Elements: There is no mention of analyzing biological samples, detecting biomarkers, or providing diagnostic information about a patient's health status.
The device is a wound care product designed to manage and treat wounds, not to diagnose a condition.
N/A
Intended Use / Indications for Use
Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions. Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers.
Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate. Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue.
Product codes
FRO
Device Description
Biatain Ag Foam Dressings are wound dressings for exuding wounds with delayed healing due to bacteria, or where there is a risk of infection. Biatain Ag Foam Dressings consist of soft, absorbing polyurethane (PU) foam pads with a moisture-permeable PU topfilm on one side and a smooth, wound-contact surface on the other side. The foam is directly on the topfilm, except for Biatain Ag Cavity which has no topfilm. The foams contain silver, which is released upon contact with wound exudate.
The dressings are available in different sizes and shapes, including squares and rectangles, with rounded corners. Biatain Ag Non-Adhesive Foam Dressings also have bevelled edges. Foam thicknesses are 3 mm or 4.4 mm.
The dressings are individually-packed in a pouch. All dressings are sterile and are for single use only.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Substantial equivalency is supported by bench testing compared to the predicate device and biocompatibility testing performed on the subject device.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc)
Not Found
N/A
0
510(k) Summary
Biatain Ag Foam Dressings
The assigned 510(k) number is: K100218
510(k) Owner's Name: Coloplast A/S
Contact Person: Rebeka A. Stoltman
Manager, Regulatory Affairs
Coloplast Corp.
1601 West River Road North
Minneapolis, MN 55411
Telephone: (612) 302-4997
Facsimile: (612) 287-4138
Email: usrst@coloplast.com
Date Prepared: January 22, 2010
FEB 17 2010
Device Name and Classification
| Trade Name: | Biatain Ag Foam Dressings |
|---|---|
| Common Name: | Topical Wound Dressing |
| Classification: | Unclassified; 21 CFR § 878.4020 |
| Classification Name: | Dressing, Wound, Drug |
| Product Code: | FRO |
Manufacturer
Coloplast A/S Holtedam 1 3050 Humlebaek, Denmark
ﺮ ﻟﻤ Establishment Registration: 9610694 Owner/Operator: 8010144
Biatain Ag Foam Dressings
- Confidential -
1
Device Description
Biatain Ag Foam Dressings are wound dressings for exuding wounds with delayed healing due to bacteria, or where there is a risk of infection. Biatain Ag Foam Dressings consist of soft, absorbing polyurethane (PU) foam pads with a moisture-permeable PU topfilm on one side and a smooth, wound-contact surface on the other side. The foam is directly on the topfilm, except for Biatain Ag Cavity which has no topfilm. The foams contain silver, which is released upon contact with wound exudate.
The dressings are available in different sizes and shapes, including squares and rectangles, with rounded corners. Biatain Ag Non-Adhesive Foam Dressings also have bevelled edges. Foam thicknesses are 3 mm or 4.4 mm.
The dressings are individually-packed in a pouch. All dressings are sterile and are for single use only.
Substantial Equivalence Claim
The modified Coloplast Biatain Ag Foam Dressings are substantially equivalent in performance, indications, design and materials to Coloplast's currently marketed Contreet Adhesive and Non-Adhesive Foam Dressings and Contreet Cavity Foam Dressings, which were cleared under 510(k)s K022416 & K033869, respectively.
Indications for Use
Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions. Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers.
Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate. Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue.
Summary & Conclusions of the Nonclinical Tests Submitted
Substantial equivalency is supported by bench testing compared to the predicate device and biocompatibility testing performed on the subject device.
Biatain Ag Foam Dressings
- Confidential -
2
Image /page/2/Picture/1 description: The image is a seal for the Department of Health & Human Services - USA. The seal is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. In the center of the seal is an abstract image of an eagle.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002
FEB 1 7 2010
Coloplast A/S % Coloplast Corporation Ms. Rebeka A. Stoltman 1601 West River Road North Minneapolis, Minnesota 55411
Re: K100218
Trade/Device Name: Biatain Ag Foam Adhesive & Non-Adhesive, & Cavity Regulatory Class: Unclassified Product Code: FRO Dated: January 22, 2010 Received: January 26, 2010
Dear Ms. Stoltman:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA), You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
Page 2 - Ms. Rebeka A. Stoltman
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.html for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/Reportal?roblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its tolloffree number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
Mark N. Mallonee
Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Indications for Use
510(k) Number (if known):
Device Name: Biatain Ag Foam Adhesive & Non-Adhesive, & Cavity
Biatain Ag Foam Adhesive & Non-Adhesive Dressings are indicated for use in the management of moderately to highly exuding leg ulcers and pressure sores. The dressing can also be used for 2nd degree burns, donor sites, post operative wounds and skin abrasions.
Biatain Ag Foam Non-Adhesive Dressings are additionally indicated for diabetic foot ulcers.
Biatain Ag Foam Cavity Dressings are indicated for deep wounds with moderate to high amounts of exudate.
Biatain Ag Foam Cavity Dressings are indicated for stage II, III and IV pressure ulcers, leg
ulcers, diabetic foot ulcers and first or second degree burns with significant loss of tissue.
Daniel Keene for MXM
Sign-Off
Division of Surgical, Orthopedic, and Restorative Devic
510(k) Number K100218
Prescription Use X (Part 21 CFR 801 Subpart D) AND/OR
Over-The-Counter Use (21 CFR 807 Subpart C)
-0
(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)